Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBCIXL)

Drug Name
Stamulumab Drug Info
Synonyms
MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
Indication
Disease Entry ICD 11 Status REF
Duchenne dystrophy 8C70 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMBCIXL

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 8 (GDF-8) TTSWPH8 GDF8_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Growth/differentiation factor 8 (GDF-8) DTT MSTN -0.737 -1.737 1.433 -1.322
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Duchenne dystrophy
ICD Disease Classification 8C70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Growth/differentiation factor 8 (GDF-8) DTT MSTN 1.64E-01 -0.06 -0.06
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00104078) Study Evaluating MYO-029 in Adult Muscular Dystrophy. U.S. National Institutes of Health.
2 Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.